Latest Commercial Expansion News

NoviqTech has formalised a key collaboration with Viva Energy on sustainable aviation fuel and agreed to acquire biochar carbon removal specialist Coralia, backed by a $1.5 million capital raise.

Fluence Corporation Limited has reported a robust FY 2025 with a 52.3% revenue increase and record new orders, driven by a strategic pivot to higher-margin Smart Product Solutions and recurring revenue streams.

Imricor Medical Systems has achieved multiple world-first procedures using real-time MRI guidance for cardiac ablation, advancing clinical trials and regulatory progress amid a strategic commercial expansion.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

HeraMED Limited has completed a $3.2 million placement to fund its global rollout of digital maternity care solutions, backed by new and existing institutional investors.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

LTR Pharma has initiated dosing in its Phase II clinical trial for SPONTAN, a rapid-acting intranasal spray targeting erectile dysfunction, marking a key step toward FDA approval and commercial expansion.

Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.

Zelira Therapeutics has raised nearly US$33 million from ThirdGate Capital to advance its HOPE® 1 drug targeting autism-related Phelan-McDermid Syndrome through FDA clinical trials. This funding milestone sets the stage for pivotal regulatory progress in the US.

Orthocell has increased its investment in Marine Biomedical to 11.7%, securing exclusive distribution rights to the innovative PearlBone™ technology as it nears FDA approval.

Proteomics International has been granted a Canadian patent for its PromarkerEso blood test, a pioneering diagnostic tool for early detection of esophageal adenocarcinoma. This milestone strengthens its global intellectual property portfolio and paves the way for commercial expansion in North America.

Orthocell has reported a record $3.2 million in quarterly revenue, marking its seventh consecutive quarter of growth, driven by strong sales of its Remplir™ nerve repair product in Australia and early traction in the US market.